A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
doi: https://doi.org/10.1101/2021.03.09.21252944
